1.76 USD
0 (0%)
1.79 USD
+0.03 (+1.7%)
We assign a fundamental rating of 3 out of 10 to CERS. CERS was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CERS have multiple concerns. While showing a medium growth rate, CERS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CERS has reported negative net income.
In the past year CERS had a positive cash flow from operations.
In the past 5 years CERS always reported negative net income.
In the past 5 years CERS reported 4 times negative operating cash flow.
1.2 Ratios
CERS's Return On Assets of -7.42% is fine compared to the rest of the industry. CERS outperforms 64.89% of its industry peers.
With a decent Return On Equity value of -25.97%, CERS is doing good in the industry, outperforming 60.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.42% | ||
| ROE | -25.97% | ||
| ROIC | N/A |
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of CERS (60.50%) is better than 60.64% of its industry peers.
CERS's Gross Margin has been stable in the last couple of years.
CERS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
2. Health
2.1 Basic Checks
CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CERS has been increased compared to 1 year ago.
CERS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CERS is higher compared to a year ago.
2.2 Solvency
CERS has an Altman-Z score of -4.36. This is a bad value and indicates that CERS is not financially healthy and even has some risk of bankruptcy.
CERS's Altman-Z score of -4.36 is on the low side compared to the rest of the industry. CERS is outperformed by 67.55% of its industry peers.
The Debt to FCF ratio of CERS is 505.38, which is on the high side as it means it would take CERS, 505.38 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 505.38, CERS is doing good in the industry, outperforming 65.96% of the companies in the same industry.
CERS has a Debt/Equity ratio of 0.79. This is a neutral value indicating CERS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.79, CERS is not doing good in the industry: 71.28% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 505.38 | ||
| Altman-Z | -4.36 |
ROIC/WACCN/A
WACC8.72%
2.3 Liquidity
A Current Ratio of 1.89 indicates that CERS should not have too much problems paying its short term obligations.
CERS's Current ratio of 1.89 is on the low side compared to the rest of the industry. CERS is outperformed by 65.96% of its industry peers.
A Quick Ratio of 1.29 indicates that CERS should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.29, CERS is not doing good in the industry: 65.43% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
CERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.27%, which is quite impressive.
CERS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.18%.
Measured over the past years, CERS shows a quite strong growth in Revenue. The Revenue has been growing by 16.50% on average per year.
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)14.18%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%14.52%
3.2 Future
The Earnings Per Share is expected to grow by 28.85% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 14.35% on average over the next years. This is quite good.
EPS Next Y-8.95%
EPS Next 2Y17.22%
EPS Next 3Y28.85%
EPS Next 5YN/A
Revenue Next Year18.38%
Revenue Next 2Y15.16%
Revenue Next 3Y14.35%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CERS. In the last year negative earnings were reported.
Also next year CERS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
65.96% of the companies in the same industry are more expensive than CERS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2012.37 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CERS's earnings are expected to grow with 28.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.22%
EPS Next 3Y28.85%
5. Dividend
5.1 Amount
No dividends for CERS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.76
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners72.59%
Inst Owner Change-2.81%
Ins Owners2.97%
Ins Owner Change1.65%
Market Cap338.08M
Revenue(TTM)225.97M
Net Income(TTM)-15.96M
Analysts80
Price Target4.76 (170.45%)
Short Float %2.86%
Short Ratio3.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)46.52%
Min EPS beat(2)-6.95%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)28.92%
Min EPS beat(4)-6.95%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)28.86%
EPS beat(12)7
Avg EPS beat(12)15.59%
EPS beat(16)11
Avg EPS beat(16)17.8%
Revenue beat(2)0
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-5.44%
Max Revenue beat(2)-5.03%
Revenue beat(4)1
Avg Revenue beat(4)-6.17%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-5.95%
Revenue beat(12)2
Avg Revenue beat(12)-6.05%
Revenue beat(16)6
Avg Revenue beat(16)-2.43%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)62.5%
EPS NQ rev (3m)57.14%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.9%
Revenue NQ rev (1m)1.32%
Revenue NQ rev (3m)-4.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.5 | ||
| P/FCF | 2012.37 | ||
| P/OCF | 94.81 | ||
| P/B | 5.5 | ||
| P/tB | 5.62 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)0
FCFY0.05%
OCF(TTM)0.02
OCFY1.05%
SpS1.18
BVpS0.32
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.42% | ||
| ROE | -25.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.5% | ||
| FCFM | 0.07% |
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
F-Score5
Asset Turnover1.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 505.38 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 248.94% | ||
| Cap/Sales | 1.5% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | -4.36 |
F-Score5
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)132.31%
Cap/Depr(5y)95.58%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-8.95%
EPS Next 2Y17.22%
EPS Next 3Y28.85%
EPS Next 5YN/A
Revenue 1Y (TTM)14.18%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%14.52%
Revenue Next Year18.38%
Revenue Next 2Y15.16%
Revenue Next 3Y14.35%
Revenue Next 5YN/A
EBIT growth 1Y19.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year159.92%
EBIT Next 3Y65.7%
EBIT Next 5YN/A
FCF growth 1Y100.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y111.99%
OCF growth 3YN/A
OCF growth 5YN/A
CERUS CORP / CERS FAQ
Can you provide the ChartMill fundamental rating for CERUS CORP?
ChartMill assigns a fundamental rating of 3 / 10 to CERS.
What is the valuation status for CERS stock?
ChartMill assigns a valuation rating of 2 / 10 to CERUS CORP (CERS). This can be considered as Overvalued.
How profitable is CERUS CORP (CERS) stock?
CERUS CORP (CERS) has a profitability rating of 2 / 10.
What is the earnings growth outlook for CERUS CORP?
The Earnings per Share (EPS) of CERUS CORP (CERS) is expected to decline by -8.95% in the next year.